Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19

被引：13

作者：

Boggiano, Cesar ^{[1
]}

Eisinger, Robert W. ^{[2
]}

Lerner, Andrea M. ^{[3
]}

Anderson, James M. ^{[2
]}

Woodcock, Janet ^{[4
]}

Fauci, Anthony S. ^{[3
]}

Collins, Francis S. ^{[2
]}

机构：

[1] NIAID, Div Aids, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[2] NIH, Off Director, Bldg 10, Bethesda, MD 20892 USA

[3] NIAID, Off Director, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA

[4] US FDA, Off Commissioner, Silver Spring, MD USA

来源：

ANNALS OF INTERNAL MEDICINE | 2022年 / 175卷 / 01期

基金：

美国国家卫生研究院;

关键词：

CONVALESCENT PLASMA THERAPY;

D O I：

10.7326/M21-3669

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

As the fourth wave of the SARS-CoV-2 pandemic encircles the globe, there remains an urgent challenge to identify safe and effective treatment and prevention strategies that can be implemented in a range of health care and clinical settings. Substantial advances have been made in the use of anti-SARS-CoV-2 antibodies to mitigate the morbidity and mortality associated with COVID-19. On 15 June 2021, the National Institutes of Health, in collaboration with the U.S. Food and Drug Administration, convened a virtual summit to summarize existing knowledge on anti-SARS-CoV-2 antibodies and to identify key unanswered scientific questions to further catalyze the clinical development and implementation of antibodies.

引用

页码：119 / +

页数：9

共 54 条

[1] A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
Lundgren J.D.
Grund B.
Barkauskas C.E.
Holland T.L.
Gottlieb R.L.
Sandkovsky U.
Brown S.M.
Knowlton K.U.
Self W.H.
Files D.C.
Jain M.K.
Benfield T.
Bowdish M.E.
Leshnower B.G.
Baker J.V.
Jensen J.-U.
Gardner E.M.
Ginde A.A.
Harris E.S.
Johansen I.S.
Markowitz N.
Matthay M.A.
Østergaard L.
Chang C.C.
Davey V.J.
Goodman A.
Higgs E.S.
Murray D.D.
Murray T.A.
Paredes R.
Parmar M.K.B.
Phillips A.N.
Reilly C.
Sharma S.
Dewar R.L.
Teitelbaum M.
Wentworth D.
Cao H.
Klekotka P.
Babiker A.G.
Gelijns A.C.
Kan V.L.
Polizzotto M.N.
Thompson B.T.
Lane H.C.
Neaton J.D.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (10) : 905 - 914
[2] COMPLEMENT IS ACTIVATED IN THE UPPER RESPIRATORY-TRACT DURING INFLUENZA-VIRUS INFECTION
BJORNSON, AB
MELLENCAMP, MA
SCHIFF, GM
[J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 143 (05): : 1062 - 1066
[3] Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, Philip J. M.
Caniels, Tom G.
van der Straten, Karlijn
Snitselaar, Jonne L.
Aldon, Yoann
Bangaru, Sandhya
Torres, Jonathan L.
Okba, Nisreen M. A.
Claireaux, Mathieu
Kerster, Gius
Bentlage, Arthur E. H.
van Haaren, Marlies M.
Guerra, Denise
Burger, Judith A.
Schermer, Edith E.
Verheul, Kirsten D.
van der Velde, Niels
van der Kooi, Alex
van Schooten, Jelle
van Breemen, Marielle J.
Bijl, Tom P. L.
Sliepen, Kwinten
Aartse, Aafke
Derking, Ronald
Bontjer, Ilja
Kootstra, Neeltje A.
Wiersinga, W. Joost
Vidarsson, Gestur
Haagmans, Bart L.
Ward, Andrew B.
de Bree, Godelieve J.
Sanders, Rogier W.
van Gils, Marit J.
[J]. SCIENCE, 2020, 369 (6504) : 643 - +
[4] SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, Peter
Nirula, Ajay
Heller, Barry
Gottlieb, Robert L.
Boscia, Joseph
Morris, Jason
Huhn, Gregory
Cardona, Jose
Mocherla, Bharat
Stosor, Valentina
Shawa, Imad
Adams, Andrew C.
Van Naarden, Jacob
Custer, Kenneth L.
Shen, Lei
Durante, Michael
Oakley, Gerard
Schade, Andrew E.
Sabo, Janelle
Patel, Dipak R.
Klekotka, Paul
Skovronsky, Daniel M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (03) : 229 - 237
[5] Use of convalescent plasma therapy in SARS patients in Hong Kong
Cheng, Y
Wong, R
Soo, YOY
Wong, WS
Lee, CK
Ng, MHL
Chan, P
Wong, KC
Leung, CB
Cheng, G
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2005, 24 (01) : 44 - 46
[6] The Collaborative Cross, a community resource for the genetic analysis of complex traits
Churchill, G
Airey, DC
Allayee, H
Angel, JM
Attie, AD
Beatty, J
Beavis, WD
Belknap, JK
Bennett, B
Berrettini, W
Bleich, A
Bogue, M
Broman, KW
Buck, KJ
Buckler, E
Burmeister, M
Chesler, EJ
Cheverud, JM
Clapcote, S
Cook, MN
Cox, RD
Crabbe, JC
Crusio, WE
Darvasi, A
Deschnepper, CF
Doerge, RW
Farber, CR
Forejt, J
Gaile, D
Garlow, SJ
Geiger, H
Gershenfeld, H
Gordon, T
Gu, J
Gu, WK
de Haan, G
Hayes, NL
Heller, C
Himmelbauer, H
Hitzemann, R
Hunter, K
Hsu, HC
Iraqi, FA
Ivandic, B
Jacob, HJ
Jansen, RC
Jjepsen, KJ
Johnson, DK
Johnson, TE
Kempermann, G
[J]. NATURE GENETICS, 2004, 36 (11) : 1133 - 1137
[7] Cohen MS, 2021, JAMA-J AM MED ASSOC, V326, P46, DOI [10.1001/jama.2021.8828, 10.1001/jama.2021.88282021.]
[8] DELGADOFERNANDE.M, ENFERM INFEC MICR CL, P2021
[9] Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI [10.1038/s41432-020-0088-4, 10.1128/CMR.00028-20]
[10] Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Dougan, M.
Nirula, A.
Azizad, M.
Mocherla, B.
Gottlieb, R. L.
Chen, P.
Hebert, C.
Perry, R.
Boscia, J.
Heller, B.
Morris, J.
Crystal, C.
Igbinadolor, A.
Huhn, G.
Cardona, J.
Shawa, I
Kumar, P.
Adams, A. C.
Van Naarden, J.
Custer, K. L.
Durante, M.
Oakley, G.
Schade, A. E.
Holzer, T. R.
Ebert, P. J.
Higgs, R. E.
Kallewaard, N. L.
Sabo, J.
Patel, D. R.
Dabora, M. C.
Klekotka, P.
Shen, L.
Skovronsky, D. M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) : 1382 - 1392

← 1 2 3 4 5 6 →